FDA Approves Mepolizumab for Treatment of Patients With COPD and an Eosinophilic Phenotype

Source: Pharmacy Times articles

Mepolizumab gains FDA approval as a promising add-on therapy for COPD patients with eosinophilic phenotype, reducing exacerbation rates significantly.
Read More